AllSci News
FDA grants Intent Bio BTD for PEP biologic in diabetic foot ulcers
Minnesota-based INTENT Biologics announced receipt of US FDA Breakthrough Therapy Designation (BTD) for PEP Biologic (Purified Exosome Product), a platelet-derived exosome biologic,…
Neurogene raises USD 125m to accelerate Rett syndrome gene therapy toward approval
New York-based Neurogene Inc. (Nasdaq: NGNE) announced the pricing of a USD 125 million public offering of common stock and pre-funded warrants on July 1,...
Alvotech secures USD 75m term loan to fund FDA resubmissions and global launches
Iceland-based Alvotech (Nasdaq: ALVO) announced a USD 75 million term loan facility on July 1, 2026, adding non-dilutive debt capital to fund R&D pipeline...
Lonza reshapes CDMO model with proprietary CNS delivery platform acquisition from Nona
Lonza has struck a deal to acquire IP rights to Nona Biosciences' single-domain antibody BBB-crossing technology, marking an unusual move by the Swiss CDMO...
Vertex expands label for Casgevy to young children with sickle cell disease
The US FDA has supplementally approved Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with sickle cell disease (SCD) with…
Abbisko to pair oral PD-L1 inhibitor with AstraZeneca's Tagrisso in combination trial for NSCLC
Shanghai-based Abbisko Therapeutics (HKEX: 02256.HK) has entered a clinical collaboration with AstraZeneca (NYSE: AZN) to evaluate lumipodlin (ABSK043), a...
Takeda bets USD 600 million on Insilico's generative AI platform for drug discovery
Takeda has struck a deal worth up to USD 600 million with Insilico Medicine (HKEX: 3696), gaining access to the company's Pharma.AI generative AI platform...
Abivax raises USD 800m in upsized offering to fund obefazimod US commercialization push
France-based Abivax SA (Euronext Paris / Nasdaq: ABVX) announced the pricing of an upsized underwritten public offering of American Depositary Shares,...
Oryzon secures EUR 37m as LSD1 inhibitor iadademstat advances
Spain-based Oryzon Genomics, S.A. (Madrid: ORY) announced a completed equity capital increase of EUR 12 million (approximately USD 14.1 million) alongside a...
Arcutis expands Zoryve’s indication to youngest psoriasis patients after FDA nod
California-based Arcutis Biotherapeutics (Nasdaq: ARQT) has received US FDA approval to expand the indication for Zoryve (roflumilast) cream 0.3% to children as…
Natera embeds Signatera into Aveta’s Phase III head and neck cancer trial
Natera, Inc. (Nasdaq: NTRA) and Massachusetts-based Aveta Biomics, Inc. announced a clinical research collaboration integrating Natera’s Signatera tumor-informed circulating tumor DNA assay…
Larimar advances first Friedreich's ataxia drug toward accelerated FDA approval with novel surrogate endpoint
Bala Cynwyd, Pennsylvania-based Larimar Therapeutics (Nasdaq: LRMR) has submitted the first module of a rolling Biologics License Application (BLA) to the...
Viatris clears path to Japan NDA for VR-205 in IgA nephropathy
Viatris Inc. (Nasdaq: VTRS) reported positive top-line results from a Phase III bridging study of VR-205 (targeted-release budesonide) in Japanese adults...
Flare Therapeutics secures USD 85m Series C to advance prostate cancer degrader program
Cambridge, Massachusetts-based Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company focused on drugging transcription factors in...
Nuvectis replenishes coffers after Haisco deal with USD 100m public offering
Fort Lee, New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the pricing of an underwritten public offering of common stock, raising USD 100...
The AllSci Brief
Free, systematic R&D and deal news. Daily.